Rxrx stock forecast.

2 days ago · The latest price target for Recursion Pharmaceuticals ( NASDAQ: RXRX) was reported by JP Morgan on Monday, November 13, 2023. The analyst firm set a price target for 10.00 expecting RXRX to rise ...

Rxrx stock forecast. Things To Know About Rxrx stock forecast.

Complete Recursion Pharmaceuticals Inc. stock information by Barron's. View real-time RXRX stock price and news, along with industry-best analysis.Ticker Symbol: RXRX: Exchange: NASDAQ: Fiscal Year: January - December: Reporting Currency: USD: IPO Price: $18.00: CIK Code: 0001601830: CUSIP Number: 75629V104 ...Analyst Forecast According to 6 analysts, the average rating for RXRX stock is "Buy." The 12-month stock price forecast is $15.33, which is an increase of 107.44% from the latest price.Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) Pre-Market Stock Quotes - Nasdaq offers pre-market quotes and pre-market activity data for US and global markets.As of July 24, 2023, 4:00 PM CST, Recursion Pharmaceuticals Inc’s stock price was $14.28. Recursion Pharmaceuticals Inc is down 7.69% from its previous closing price of $15.47. During the last market session, Recursion Pharmaceuticals Inc’s stock traded between $14.36 and $16.09.

Andrew Hopkins. https://www.exscientia.ai. Exscientia plc, an artificial intelligence-driven pharmatech company, engages in discovering, designing, and developing drugs. The company offers end-to-end solution of artificial intelligence (AI) and technologies for target identification, drug candidate design, translational models, and patient ...

What this means: Recursion Pharmaceuticals Inc Cl (RXRX) gets an Overall Rank of 60, which is an above average rank under InvestorsObserver's stock ranking system. Our system considers the available information about the company and then compares it to all the other stocks we have data on to get a percentile-ranked value.

For RXRX stock, which has suffered sharp losses against a long-term framework, AI may put the underlying company on the right track again. Still, investors need to be aware of separating the ...Recursion Pharmaceuticals (RXRX 7.88%) is a biotech that's riding a hype wave unlike any other. By staking its fame and investors' cash on its artificial intelligence (AI) platform for drug ...On the bottom line, Recursion's net loss per share of $0.38 remained flat compared to the prior-year quarter. The company ended the period with $405.9 million in cash and equivalents, which does ...Created with Sketch. when trading, helping you to optimize your price and have a successful order execution. Investors may trade in the Pre-Market (4:00-9:30 a.m. ET) and the After Hours Market (4 ...RXRX has gained $0.29 from the previous closing price of $5.16 on volume of 1,340,878 shares. Over the past year the S&P 500 is higher by 3.38% while RXRX is lower by -1.98%. RXRX lost -$1.36 per share the over the last 12 months. Click Here to get the full Stock Report for Recursion Pharmaceuticals Inc stock.

View the latest Recursion Pharmaceuticals Inc. (RXRX) stock price, news, historical charts, analyst ratings and financial information from WSJ.

Recursion Pharmaceuticals Stock Prediction. BSX. 63

Find the latest ARK Genomic Revolution ETF (ARKG) stock quote, history, news and other vital information to help you with your stock trading and investing.According to 6 stock analysts, the average 12-month stock price forecast for RXRX stock stock is $15.33, which predicts an increase of 120.26%. The lowest target is $8.00 and the highest is $33. On average, analysts rate RXRX stock stock as a buy.Sep 22, 2023 · According to data from CNN Money, the company had 7 analysts offering 12-month price forecasts. The median target price was $14.00, with a high estimate of $35.00 and a low estimate of $9.00. The consensus among the 7 polled investment analysts was to hold the stock of Recursion Pharmaceuticals Inc. This rating had remained steady since ... Shares of Recursion Pharmaceuticals (RXRX 1.18%) ... Nvidia's stock was also up nearly 3%, but that may have had more to do with the inflation report that buoyed the market on Wednesday. In May ...Planning a trip can be an exciting but challenging task. From booking accommodations to creating an itinerary, there are countless details to consider. One crucial aspect that should never be overlooked is checking the 7-day weather forecas...What this means: Recursion Pharmaceuticals Inc Cl (RXRX) gets an Overall Rank of 60, which is an above average rank under InvestorsObserver's stock ranking system. Our system considers the available information about the company and then compares it to all the other stocks we have data on to get a percentile-ranked value.

Nov 13, 2023 · Future criteria checks 0/6. Recursion Pharmaceuticals's revenue and earnings are forecast to decline at 2.9% and 12.8% per annum respectively. EPS is expected to decline by 9% per annum. Return on equity is forecast to be -471.6% in 3 years. (See RXRX stock forecast) To find good ideas for stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.beststocks.com4.31%. €8.59M. RXRX | Complete Recursion Pharmaceuticals Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview. Analyst Forecast According to 6 analysts, the average rating for RXRX stock is "Buy." The 12-month stock price forecast is $15.33, which is an increase of 107.44% from the latest price.Recursion Pharmaceuticals Stock Chart and Share Price Forecast, Short-Term "RXRX" Stock Prediction for Next Days and Weeks Walletinvestor.com Recursion Pharmaceuticals Inc (RXRX) Forecast Chart, Long-Term Predictions for Next Months and Year: 2023, 2024

As for revenue growth, note that RXRX's revenue has grown 65.02% over the past 12 months; that beats the revenue growth of 92.59% of US companies in our set. Stocks with similar financial metrics, market capitalization, and price volatility to RECURSION PHARMACEUTICALS INC are TSP, ALGS, FUSN, ITOS, and PRAX. RXRX's SEC …NVIDIA Corporation Common Stock. $416.10 +5.93 +1.45%. ARM. Arm Holdings plc American Depositary Shares. $51.32 -0.84 -1.61%. Find the latest analyst research for Recursion Pharmaceuticals, Inc ...

Recursion Pharma may be a biotech stock, but it scored a $50 million investment from Nvidia to fund its AI technology in mid-July - making NVDA a significant stakeholder in RXRX. The partnership ...Recursion Pharmaceuticals Inc. 7.06. Delayed Data. As of Nov 17. +0.39 / +5.85%. Today’s Change. 4.54. Today ||| 52-Week Range. 16.75.Nasdaq.com will report pre-market and after hours trades. Pre-Market trade data will be posted from 4:15 a.m. ET to 7:30 a.m. ET of the following day. After Hours trades will be posted from 4:15 p ... Some recommended hot buy stocks, all down. But that got me to look closer. Thursdays market dump? This stock slid, then immediately was bought up with a climb all throughout the day. Hmm. Caught my eye little stock. Zack’s says you’re just a hold now, so why are you doing well this week? Tradingview says RXRX is a strong buy.The company's shares are currently changing hands for $7.07 apiece, but the consensus one-year target for the stock is $15.57, which implies that it could rise by about 120% over the next 12 months.Planning a trip can be an exciting but challenging task. From booking accommodations to creating an itinerary, there are countless details to consider. One crucial aspect that should never be overlooked is checking the 7-day weather forecas...how to read an earnings report. Nasdaq provides visual representation of analyst expected earnings growth. Read our earnings report guide before you consider the forecast information when making ...Uncover the latest insider trading activity for Recursion Pharmaceuticals, Inc. (RXRX). Know which insiders are buying and selling along with top shareholders and ownership breakdown. ... NasdaqGS:RXRX Stock Report. Mkt Cap: US$1.5b. Add to watchlist. Company Overview; 1 Valuation; 2 Future Growth; 3 Past Performance; 4 Financial …Dec 1, 2023 · RXRX Stock Overview. Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery.

RXRX Quantitative Stock Analysis - Benjamin Graham. November 18, 2023 — 01:00 pm EST. Written by John Reese for Validea ->. Below is Validea's guru fundamental report for RECURSION ...

Industry. Biotechnology. No executives to display. Corporate headquarters. --, --. Find real-time RXRX - Recursion Pharmaceuticals Inc stock quotes, company profile, news and forecasts from CNN ...

Prior to today’s announcement, RXRX stock sat in negative territory for the year. Now, at the time of this writing, shares are up more than 50% year-to-date (YTD).Zillow is worth $8.3 billion right now, so if it reaches its 2025 sales estimate and continues to grow thereafter, it should breeze past a $10 billion valuation by 2030. 2. Duolingo: Potential ...Recursion Pharmaceuticals Inc. research and ratings by Barron's. View RXRX revenue estimates and earnings estimates, as well as in-depth analyst breakdowns.See Recursion Pharmaceuticals, Inc. (RXRX) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades. As of 03:16PM EST. Market open. See Recursion Pharmaceuticals, Inc. (RXRX) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades.Insiders have purchased a total of 581,017 RXRX shares in the last 24 months for a total of $4,440,853.30 bought. Which Recursion Pharmaceuticals insiders have been selling company stock? The following insiders have sold RXRX shares in the last 24 months: Blake Borgeson ($2,846,394.44), Christopher Gibson ($14,439,192.59), …In the world of business, cash flow is king. Having a clear understanding of your company’s cash flow is essential for making informed financial decisions and ensuring the long-term success of your business.The Recursion Pharmaceuticals, Inc. stock price gained 7.88% on the last trading day (Friday, 1st Dec 2023), rising from $6.85 to $7.39. During the last trading day …Cathie Wood’s ARK Investment bought 1.89M shares of Recursion Pharmaceuticals November 27, 2023TipRanks. Analysts Offer Insights on Healthcare Companies: Recursion Pharmaceuticals (RXRX ...Investors looking for stocks that can put up dramatic gains ... (RXRX 7. 88%) have fallen by ... Zynteglo's U.S. launch will be extra difficult to forecast because its strategy involves returning ...Recursion Pharmaceuticals, Inc. (RXRX) share price prediction for 2023, 2024, 2025, 2026 and 2027. RXRX one year forecast. Recursion Pharmaceuticals stock monthly and ...

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel ...People use statistics daily for weather forecasts, predicting disease, preparing for emergencies, medical research, political campaigns, tracking sales, genetics, insurance, the stock market and quality testing.Heading out for an outdoor adventure? Whether you’re planning a picnic, a hiking trip, or a beach day, one essential tool you need in your arsenal is a detailed weather 10 day forecast.All 39 ARKG ETF Holdings. The portfolio of Cathie Wood updated daily. These are the positions, trades, and weight of all companies in her ARKG Genomic Revolution ETF. Search tickers or categories... Trader's Guide 2024 Ships December 21st.Instagram:https://instagram. online options brokersis blue cross insurance goodtop natural gas stocksinvesting in insurance RXRX : RECURSION PHARMACEUTICALS-A stock forecast by Wall Street Analysts. The average RECURSION PHARMACEUTICALS-A stock forecast from last 6 month is $16.9, and this show a 3.7% increase in average from the prior price target of the each prediction.30 сент. 2023 г. ... NASDAQ: RXRX. Recursion Pharmaceuticals. Recursion Pharmaceuticals Stock Quote. Market Cap. $2B. Today's Change. (0.43%) $0.03. Current Price. new gold inc stockiso 22 coins The average one-year price target for Recursion Pharmaceuticals Inc - ( NASDAQ:RXRX) has been revised to 17.17 / share. This is an increase of 7.12% from the prior estimate of 16.03 dated August ... mortgage lenders in north carolina Dec 1, 2023 · View Recursion Pharmaceuticals, Inc RXRX investment & stock information. Get the latest Recursion Pharmaceuticals, Inc RXRX detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. Meta Platforms ( META ): META’s revenues climbed 23% to $34.15 billion in its most recent quarter. Teradyne ( TER ): Resilient Teradyne outshone in the third quarter with an 80-cent Non-GAAP EPS ...